Brooke successful acquisition of companies MOLECUBES NV: modular workbench to further broaden the nuclear molecular imaging products
On November 19, 2021, Ghent, Belgium.Brooke recently announced the acquisition of MOLECUBES NV, a vibrant innovative desktop preclinical nuclear molecular imaging (NMI) system development company.The acquisition to further strengthen the brooke as preclinical and conversion imaging research field's leading supplier of NMI solutions.
Brooke preclinical imaging products series with its global influence, will work with MOLECUBES modular desktop CUBES ™ system, provide a wider range of NMI products, further accelerate preclinical NMI in the global academic medical center and the application of biological pharmaceutical companies.
Brooke BioSpin preclinical imaging President wulff i. Dr Jung commented: "nuclear molecular transformation of preclinical and imaging studies is a growing market segment, brooke's high-performance synchronous PET/MR and PET/SPECT/CT instrument and PMOD ™ PET data analysis software has been trusted by the customers in the market.Acquisition MOLECUBES, let brook in NMI products series of preclinical research adds to the extensible benchtop instruments.In the future, we will and MOLECUBES r&d, application and service team to work together, common NMI specializing in providing quality products and solutions."
Professor MOLECUBES CEO: likely Van Holen
As of Ghent in Belgium in 2015 the establishment of a fast growing company, MOLECUBES research and development and sales of high-end PET, SPECT and CT CUBES ™ system, has successfully installed for the world's leading industry users more than 70 sets of systems.Modular desktop CUBES ™ is the brooke integration console preclinical small animal imaging system.
MOLECUBES will continue to be a brook BioSpin preclinical imaging department of an innovative and flexible operation team, MOLECUBES customers can continue to communicate through existing channels, its research and application team will work with brooke preclinical imaging experts, constantly promote the NMI technology, software, work process and application.
MOLECUBES income of around 5 million euros in fiscal year 2020, the acquisition of financial details were not disclosed.
About brooke (Nasdaq: BRKR)
Brooke is committed to supporting scientists acquire the groundbreaking scientific discoveries and new applications are developed to improve the quality of life of human beings.Brooke's science and technology of high performance instruments and high value analysis and diagnosis of solution, allow scientists to the molecules, cells and micro level to explore the mysteries of life and material.In close cooperation and user, brooke devotes to the scientific and technological innovation, improve productivity and achieve the success of the user.Our business areas include molecular life science research, and drug application, microscope and nanometer analysis, industrial application, cell biology, preclinical imaging, clinical phenotype omics, proteomics research and clinical microbiology and so on.
About MOLECUBES
MOLECUBES Ghent in Belgium, which is a molecular imaging for preclinical research instrument manufacturers.MOLECUBES provides a modular platform for the desktop, by PET and SPECT and CT CUBES before clinical ™ imager.CUBES form an extensible platform, with compact covers an area of high flux research.MOLECUBES mission is to promote the field of preclinical imaging effect, the company's more than 70 sets of CUBES have been successfully installed in academic institutions, research hospital, biological pharmaceutical companies, and contract research organization of the leading research facilities.
CUBES is used for small animal molecular imaging compact micro - CT, micro - SPECT and micro - a PET scanner, can be used as an independent system or modular combinations.
Beta - CUBE: high-performance preclinical PET scanner
X - CUBE: high-performance pre-clinical CT scanner
Gamma - CUBE: high-performance preclinical SPECT scanners
Investor relations contacts:
T: + 1 (978) 663-3660, ext. 1479
E:Investor.Relations@bruker.com
Media contacts:
Thorsten Thiel, Ph. D.
The VP of Group Marketing
Bruker BioSpin
T: + 49 (721) 5161-6500
E:pr@bruker.com
